Skip to main content

Table 2 Types of TP53 mutation and treatment outcome in 14 AML/ MDS patients

From: TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

No Gender Age
(y)
Disease Chromosome/ gene mutations TP53 mutation type (% variant allele frequency) Treatment regimen (status) Time from diagnosis to death (Mo)
1 F 57 T-AML 46,XX,del(5)(q15q33),inv.(7)(p13p22),der(11)
NPM1wt/FLT3wt/CEBPAwt
A249S (17.7) untreated (dead) 0.5
2 F 68 T-MDS (EB) 44 ~ 46,XX,add(5)(q11.2),-7,del(7)(q22), dic(7;14)(q11.2;p13),add(12)(q24.3),-18
NPM1wt/FLT3wt/CEBPAwt
T220C (41.3),
R290C (58.7)
azacitidine (dead) 4
3 F 64 T-AML 46,XX,t(1;10)(p13;p13),-5,add(5)(q31),add12(p13)
NPM1wt/FLT3wt/CEBPAwt
R248W (44.3) untreated (dead) 3
4 M 32 AML 46,XY,del(12)(p11),i(8)(q10),der(10),del(1)(p21)
NPM1wt/FLT3wt/CEBPAwt
V31I (87.3)
S241F (19.4)
7/3 (dead) 5
5 F 59 AML 46,XX,add19(p13.3)
NPM1wt/FLT3wt/CEBPAwt
R290C (41.6) 7/3 (dead) 4
6 M 71 AML 45,XY,-10,-12,-20,+ 8,+ 9
NPM1wt/FLT3wt/CEBPAwt
T220C (48) untreated (dead) 1
7 M 43 AML 42,XY,der(1)del(1)(p13p22),-3,der(5)t(5;15) (q11.2;q11.2),-7,add(8)(q24.1),-12,-15,add(8),der(8)
NPM1wt/FLT3wt/CEBPAwt
C238Y (43) 7/3 (dead) 12
8 M 74 MDS-EB 45,XY,-7
NPM1wt/FLT3wt/CEBPAwt
A249S (14.2) azacitidine (alive) 19
9 M 77 Secondary AML 44,XY,del(3)(q21q27),-3,-12,-18,+ 21
NPM1mu/FLT3-ITDmu/ CEBPAwt
R282W (100) untreated (dead) 1
10 F 42 AML 45,XX,-7
NPM1wt/FLT3wt/CEBPAwt
T220C (52.7)
R290C (35.8)
untreated (dead) 1
11 M 42 AML 47,XY,+ 1
NPM1mu/FLT3-ITDmu/ CEBPAwt
V31I (47.7) 7/3 (dead) 6
12 M 68 Secondary AML 46,XY
NPM1wt/FLT3wt/CEBPAwt
V31I (23.1) untreated (dead) 1
13 M 88 AML 47,XY,+ 8
NPM1wt/FLT3wt/CEBPAwt
R290C (66.2) untreated (dead) 4
14 M 71 Secondary AML 46,XY
NPM1mu/FLT3-ITDmu/ CEBPAwt
A249S (11.3) azacitidine (dead) 16